retatrutide triple g - retatrutide, triple GIP/GLP-1/GCGR agonist New weight-loss drug rivaling bariatric

2022;34:e2203236

I am both surgeon and patient

I think that sometimes that's also what the patient needs to see - it's actually harming me." Varney said many of the products are sold through what is often referred to as the gray market, meaning they are distributed outside official regulatory channels and are frequently labeled "for research use only." She also pointed to social media marketing as a major driver of consumer interest

Tirzepatide Plus Tirzepatide Plus is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist, representing a new class of medicines studied for the treatment of obesity